Skip to main content
. 2024 Feb 15;15(2):145. doi: 10.1038/s41419-024-06503-1

Fig. 4. Cystine supplementation inhibits CD8+ T-cell ferroptosis and boosts anti-tumor immunity.

Fig. 4

a–c CD8+ T cells were incubated in B16F10 supernatant with PBS or additional 200 μmol/L cystine for 48 h (n = 3 per group), and cell viability was detected by CCK8 assay (a). The levels of lipid peroxidation were detected using BODIPY C11 staining (b). Cytokine secretion by the indicated T cells was measured by flow cytometry (c). d Diagram of intratumoral injection of PBS or cystine in B16F10 tumors (n = 6 per group). e, f Tumor size (e), tumor volume and tumor weight (f) of the indicated groups. g The levels of lipid peroxidation in the indicated tumor-infiltrating CD8+ T cells. h–j Flow cytometry analysis of the percentages of PD-1+TIM-3+ subset (h), CD62L+CD44+ subset (i), and TCF1 expression (j) in the tumor-infiltrating CD8+ T cells. k, l IL-2 (k), IFNγ and TNFα secretion (l) of the indicated T cells. Each symbol represents one individual. Data are mean ± s.e.m. p values are measured by two-tailed unpaired Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.01.